Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Key Takeaways
Bone loss is the thread connecting two of the most prevalent chronic conditions in aging populations: osteoporosis and periodontitis. One attacks the skeleton systemically, weakening the microarchitecture of cortical and trabecular bone until fracture risk becomes life-threatening. The other attacks the jawbone locally, dismantling the alveolar support structure that holds the teeth until mobility and tooth loss follow. They are frequently treated as entirely separate clinical problems — by entirely separate clinical teams.
The evidence says otherwise. Osteoporosis and periodontal disease are highly prevalent chronic conditions that share common risk factors and biological pathways, and increasing evidence suggests a bidirectional relationship — though findings remain heterogeneous and evolving. A January 2026 narrative review published in Dentistry Journal, drawing on human studies from major electronic databases, provides the most current synthesis of this relationship — its mechanisms, its clinical implications, and the gaps that remain.
For practising periodontists and implant surgeons, this evidence base is not academic. It shapes how patients should be assessed, how antiresorptive medications should be managed, and when referral to medicine is both appropriate and necessary.
The Scale of the Problem
The numbers are significant on both sides. Osteoporosis affects over 200 million individuals globally, predominantly postmenopausal women, and is characterised by reduced bone mineral density and microarchitectural deterioration leading to elevated fracture risk. Periodontal diseases affect nearly 47% of adults over 30 worldwide, involving inflammatory destruction of tooth-supporting structures driven by dysbiotic oral biofilms, resulting in alveolar bone loss and potential tooth mobility.
In 2025, the cost of osteoporotic fractures is projected to rise over 50% from $17 billion in 2005 — a trajectory that reflects both population ageing and the inadequacy of current prevention strategies. Periodontitis, meanwhile, remains dramatically undertreated across all demographics. The intersection of these two conditions in older patients — particularly postmenopausal women — represents a significant and underaddressed clinical challenge.
One Direction: How Osteoporosis Worsens Periodontitis
The primary pathway in this direction runs through the alveolar bone. Osteoporosis features systemic degenerative bone loss leading to loss of skeletal cancellous microstructure and subsequent fracture risk, while periodontitis involves local inflammatory bone loss following infectious breach of the alveolar cortical bone. The question is whether the systemic bone fragility of osteoporosis amplifies the local bone destruction of periodontitis — and the evidence increasingly suggests it does.
Most studies support an association between reduced bone mineral density and increased severity of periodontal disease, including greater alveolar bone loss and attachment loss. The alveolar bone, despite its specialised role in tooth support, is still bone — subject to the same systemic regulatory mechanisms, hormonal influences, and inflammatory mediators that govern skeletal bone mineral density elsewhere in the body.
The hormonal dimension is particularly significant in postmenopausal women. Estrogen deficiency following menopause drives accelerated bone resorption across the skeleton — and the alveolar ridge is not spared. Shared risk factors such as aging, hormonal changes including postmenopausal estrogen deficiency, and lifestyle factors like smoking and poor nutrition further strengthen this association. Osteoporosis may exacerbate periodontitis by reducing alveolar bone density, while periodontal inflammation can elevate the expression of systemic biomarkers of bone resorption, influencing osteoporosis progression.
A useful clinical screening tool in this population is the FRAX fracture risk assessment score. Women with a FRAX score above the intervention threshold have a significantly greater chance of presenting with severe periodontitis — suggesting that FRAX, already widely used in medical practice, could serve as a meaningful prompt for periodontal referral in primary care and rheumatology settings.
The Other Direction: How Periodontitis May Affect Systemic Bone
This pathway is less well established, but increasingly well supported. Periodontal inflammation can elevate the expression of systemic biomarkers of bone resorption, influencing osteoporosis progression — creating a feedback loop in which localised gingival inflammation contributes to the systemic bone loss burden.
The mechanism centres on the RANKL/OPG axis — the receptor activator of nuclear factor-κB ligand system that governs the balance between osteoclast and osteoblast activity throughout the skeleton. In periodontitis, the inflamed periodontal tissue is a significant source of RANKL, the signalling molecule that drives osteoclast differentiation and activation. Elevated local RANKL production drives alveolar bone resorption directly — but RANKL also enters the systemic circulation, where it may influence bone turnover at skeletal sites remote from the mouth.
Both diseases involve an imbalance in bone remodelling processes, with excessive osteoclast activity over osteoblast activity, leading to bone resorption — systemic in osteoporosis, localised in periodontitis — and dysbiosis of the gut and oral microbial communities plays a critical role in both conditions, with gut dysbiosis influencing systemic inflammation and bone metabolism.
The MRONJ Problem: When Osteoporosis Treatment Becomes a Dental Risk
For the practising periodontist and implant surgeon, the most clinically urgent aspect of the osteoporosis-periodontitis relationship is not the shared pathophysiology — it is the medication interface. The drugs most commonly used to treat osteoporosis carry a risk of medication-related osteonecrosis of the jaw (MRONJ), one of the most serious and challenging complications in oral medicine.
MRONJ is associated with several drug classes beyond bisphosphonates, including RANKL inhibitors, antiangiogenic agents, corticosteroids, chemotherapies, and immunomodulators — with the mechanism rooted in suppressed osteoclast function, microvascular impairment, dysregulated immunity, and diminished soft-tissue healing.
The risk differential between patient populations is stark. For patients with malignant disease taking bisphosphonates and denosumab, the incidence of MRONJ is up to 15%, in contrast to 0.01% in patients taking bisphosphonates for osteoporosis. That low incidence figure for osteoporosis patients is reassuring — but it should not breed complacency, given the very large number of patients in this category and the severity of the condition when it does occur.
Periodontal disease itself compounds this risk meaningfully. The risk of MRONJ increased significantly when tooth extraction was performed in patients diagnosed with periodontal disease, and periodontal diseases should therefore be proactively managed in patients taking bisphosphonates. Furthermore, recent evidence suggests that chronic dental infections — including untreated apical periodontitis and advanced periodontal disease — may act as independent risk factors by maintaining a state of persistent local inflammation and compromising bone integrity, creating a favourable microenvironment for osteonecrosis even in the absence of dental procedures.
This reframes how periodontitis management should be understood in the bisphosphonate patient: treating active periodontal disease is not merely good dental care — it is a direct MRONJ risk reduction strategy.
New Data on Drug Holidays: What the Evidence Now Says
One of the most practically useful findings to emerge in 2025 concerns the timing of dental procedures in patients taking intravenous bisphosphonates. A major study published in Nature Communications in May 2025 used a nationwide retrospective cohort of 152,299 older adults with osteoporosis to analyse the relationship between bisphosphonate discontinuation and MRONJ risk around dental extraction. The risk was substantially lower when treatment was paused for more than 90 days, and lowest when the pause exceeded one year — with the risk reduction appearing more consistent with ibandronate, whereas with zoledronate, only pauses longer than one year showed a meaningful association.
This is an important nuance. The guidance not to routinely recommend drug holidays — based on the established long skeletal half-life of bisphosphonates and limited earlier evidence of benefit — may need to be revisited for intravenous bisphosphonates in the context of major dental procedures, and the drug-specific differences in risk reduction deserve attention in clinical decision-making. Collaborative discussion with the prescribing physician remains essential.
The implant-specific picture is also becoming clearer. Low-certainty evidence suggests that antiresorptive therapy for osteoporosis may actually reduce dental implant failure — likely by enhancing bone density and osseointegration — while bisphosphonates are associated with MRONJ in patients with osteoporosis receiving dental implants with moderate certainty. The clinical calculus for implant placement in a bisphosphonate patient therefore involves a genuine trade-off that warrants individualised discussion and, where necessary, specialist input.
The Integrated Care Imperative
The clinical implications of this evidence point clearly toward greater interdisciplinary collaboration. Dentists should consider osteoporosis screening in postmenopausal women with severe periodontitis, particularly those with multiple tooth loss or radiographic alveolar rarefaction. Conversely, endocrinologists and rheumatologists managing osteoporosis should inquire about oral health and refer patients for periodontal evaluation, especially those receiving antiresorptive therapy. Pretreatment dental clearance is essential before initiating bisphosphonates or denosumab to minimise the risk of osteonecrosis of the jaw.
For dental practitioners, the practical checklist includes: recording full medication history at every recall appointment, with explicit notation of bisphosphonates, denosumab, and antiangiogenic agents; assessing MRONJ risk before any invasive procedure; proactively managing active periodontal disease before antiresorptive therapy begins; and establishing communication pathways with prescribing physicians around the timing of dental procedures.
For the medical profession, the reciprocal obligation is equally clear. A patient with osteoporosis about to start bisphosphonate therapy who has not had a dental assessment is a patient at avoidable risk. Antiresorptive agent bisphosphonate therapy is effective in preventing bone loss, but may lead to osteonecrosis of the jaw — making pretreatment dental evaluation and ongoing oral hygiene maintenance essential.
What Remains Uncertain
The bidirectional relationship is well supported — but its magnitude and causal direction remain areas of active investigation. Variability in study design, diagnostic criteria, and confounding factors limits definitive conclusions, and future well-designed longitudinal studies are needed to clarify causality and inform preventive and therapeutic strategies.
The gut microbiome dimension is particularly early-stage. The concept that oral dysbiosis in periodontitis can influence gut microbial composition, and through that route affect systemic inflammation and bone metabolism, is mechanistically compelling — but the clinical evidence remains limited. It represents, however, a significant area of future research that could further strengthen the case for treating periodontitis as a whole-body concern rather than a localised dental problem.
Conclusion
Osteoporosis and periodontitis are not two separate problems that happen to coexist in aging patients. They are connected — through shared inflammatory pathways, shared hormonal drivers, shared risk factors, and shared biological mechanisms of bone resorption. Managing one in isolation from the other is, in many patients, clinically inadequate.
For dental practitioners, recognising the osteoporotic patient as a patient at elevated periodontal risk — and the severely periodontally compromised postmenopausal patient as one who may warrant osteoporosis screening — is both evidence-based and patient-centred. For the medical profession, the message is simpler still: before starting a patient on antiresorptive therapy, check their teeth.
Sources: Dentistry Journal, January 2026 (Alwithanani N, narrative review, Cureus 17(11):e97943, November 2025); Springer Nature/Advances in Experimental Medicine and Biology, 2026 (Contaldo M, Oral Immunology); Nature Communications, May 2025 (Nationwide bisphosphonate drug holiday cohort, n=152,299); Endocrine Practice, September 2025 (Mirza et al., systematic review and meta-analysis); MDPI Journal of Clinical Medicine, June 2025 (BRONJ 10-year analysis); Frontiers in Pharmacology, 2023 (phytoestrogens/postmenopausal review); Current Osteoporosis Reports, PMC.
